Literature DB >> 16982882

Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.

Seung-Woo Lee1, Yunji Park, Aihua Song, Hilde Cheroutre, Byoung S Kwon, Michael Croft.   

Abstract

Members of the TNFR family are thought to deliver costimulatory signals to T cells and modulate their function and survival. In this study, we compare the role of two closely related TNFR family molecules, OX40 and 4-1BB, in generating effector CD8 T cells to Ag delivered by adenovirus. OX40 and 4-1BB were both induced on responding naive CD8 T cells, but 4-1BB exhibited faster and more sustained kinetics than OX40. OX40-deficient CD8 T cells initially expanded normally; however, their accumulation and survival at late times in the primary response was significantly impaired. In contrast, 4-1BB-deficient CD8 T cells displayed hyperresponsiveness, expanding more than wild-type cells. The 4-1BB-deficient CD8 T cells also showed enhanced maturation attributes, whereas OX40-deficient CD8 T cells had multiple defects in the expression of effector cell surface markers, the synthesis of cytokines, and in cytotoxic activity. These results suggest that, in contrast to current ideas, OX40 and 4-1BB can have a clear functional dichotomy in modulating effector CD8 T cell responses. OX40 can positively regulate effector function and late accumulation/survival, whereas 4-1BB can initially operate in a negative manner to limit primary CD8 responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982882     DOI: 10.4049/jimmunol.177.7.4464

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  OX40 promotes obesity-induced adipose inflammation and insulin resistance.

Authors:  Bing Liu; Hengchi Yu; Guangyong Sun; Xiaojing Sun; Hua Jin; Chunpan Zhang; Wen Shi; Dan Tian; Kai Liu; Hufeng Xu; Xinmin Li; Jie Yin; Xu Hong; Dong Zhang
Journal:  Cell Mol Life Sci       Date:  2017-06-13       Impact factor: 9.261

Review 2.  Versatile CAR T-cells for cancer immunotherapy.

Authors:  Fuliang Chu; Jingjing Cao; Sattva S Neelalpu
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

3.  CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Authors:  Harry Z Qui; Adam T Hagymasi; Suman Bandyopadhyay; Marie-Clare St Rose; Raghunath Ramanarasimhaiah; Antoine Ménoret; Robert S Mittler; Scott M Gordon; Steven L Reiner; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2011-08-31       Impact factor: 5.422

4.  OX40 is a potent immune-stimulating target in late-stage cancer patients.

Authors:  Brendan D Curti; Magdalena Kovacsovics-Bankowski; Nicholas Morris; Edwin Walker; Lana Chisholm; Kevin Floyd; Joshua Walker; Iliana Gonzalez; Tanisha Meeuwsen; Bernard A Fox; Tarsem Moudgil; William Miller; Daniel Haley; Todd Coffey; Brenda Fisher; Laurie Delanty-Miller; Nicole Rymarchyk; Tracy Kelly; Todd Crocenzi; Eric Bernstein; Rachel Sanborn; Walter J Urba; Andrew D Weinberg
Journal:  Cancer Res       Date:  2013-10-31       Impact factor: 12.701

5.  Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines.

Authors:  Jennifer D Bassett; Stephanie L Swift; Heather VanSeggelen; Joanne A Hammill; A J Robert McGray; Carole Evelegh; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

6.  CD137 is required for M cell functional maturation but not lineage commitment.

Authors:  En Hui Hsieh; Xiomara Fernandez; Jing Wang; Mary Hamer; Stephanie Calvillo; Michael Croft; Byoung S Kwon; David D Lo
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

7.  Biphasic role of 4-1BB in the regulation of mouse cytomegalovirus-specific CD8(+) T cells.

Authors:  Ian R Humphreys; Seung-Woo Lee; Morgan Jones; Andrea Loewendorf; Emma Gostick; David A Price; Chris A Benedict; Carl F Ware; Michael Croft
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

Review 8.  The role of OX40-mediated co-stimulation in T-cell activation and survival.

Authors:  William L Redmond; Carl E Ruby; Andrew D Weinberg
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

Review 9.  The significance of OX40 and OX40L to T-cell biology and immune disease.

Authors:  Michael Croft; Takanori So; Wei Duan; Pejman Soroosh
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

10.  Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.

Authors:  Marie T Kim; Martin J Richer; Brett P Gross; Lyse A Norian; Vladimir P Badovinac; John T Harty
Journal:  J Immunol       Date:  2015-09-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.